Quick Takeaways: Why It Matters? ECO’s licence of Vaxinano’s late‑stage sheep toxoplasmosis vaccine gives it a low‑cost, de‑risked way to add a high‑value preventative product that directly tackles a major cause of abortion and lamb losses, with peak sales estimated a...
Quick Takeaways: Why It Matters? The deal strengthens Magapor’s ability to expand beyond its 60+ country footprint by adding growth capital for R&D, commercial expansion and product development in a niche but defensible livestock-reproduction category, while allowing the Mena Gericó fa...
Quick Takeaways: Why It Matters? Zoetis’ EC approval of Poulvac Procerta HVT-ND turns its single-dose, dual ND+Marek’s protection into a mainstream EU option, which should drive rapid adoption as producers shift from multi-vaccine schedules to a streamlined, in‑ovo or hatch-day protocol th...
Quick Takeaways: Why It Matters? ECO Animal Health’s EU launch of Ecovaxxin MS is a meaningful commercial milestone because it converts the company’s own R&D pipeline into a marketed product and gives it a differentiated position in poultry vaccines. With access to a market spanning mo...
20. ImmuCell Revenue: $18.6M Founded Year: 1982 Market Cap: $35.11M Total Employees: ~70 Headquarters: Maine, United States Stock Exchange: NASDAQ 19. Hester Pharmaceuticals & Biotech Revenue: $32M Founded Year: 1987 Market Cap: $150.13 Tota...
